Walmart Stock Slides as U.S. Sales Hit by Falling Drug Prices

Walmart's shares experienced a notable decline after the retail giant announced its second-quarter earnings, revealing that its U.S. comparable sales growth fell to its lowest level in over six years. This deceleration was primarily attributed to the impact of falling drug prices.

The company reported a 2.6% increase in U.S. comparable sales, excluding fuel, which not only missed analyst expectations but also marked the slowest pace of growth for the retailer in over six years. Specifically, this was the weakest growth since the fourth quarter of 2020, when sales increased by 1.9%. This slowdown was largely driven by pressure in its pharmacy unit, stemming from federal Medicare prescription drug regulations and a general decline in prices for certain medications, including GLP-1 drugs.

Despite the softness in comparable sales, Walmart's overall financial performance in the second quarter surpassed some expectations. The company reported total revenue of $187.9 billion, exceeding analyst estimates of $186.8 billion. Adjusted earnings per share also beat consensus forecasts, coming in at $0.80 to $0.81 against an expected $0.74. However, investor focus remained squarely on the decelerating sales growth rather than the overall top and bottom-line beats. Walmart CEO John Furner commented on the strong performance in other areas, particularly e-commerce.

Following the earnings announcement, Walmart's stock (WMT) tumbled by approximately 6% to 7% in pre-market trading, reflecting significant investor concerns over the slowed sales momentum. As a key barometer for the U.S. economy and the health of the American consumer, Walmart's performance often influences broader market sentiment. This particular slowdown intensified worries about a potential weakening in overall consumer spending momentum.

The pressure on drug prices is part of a broader trend of price deflation within the U.S. prescription drug market, influenced by federal government policies aimed at reducing healthcare costs. This development occurs at a time when U.S. consumers are navigating various economic pressures, including persistent inflation and higher costs for everyday goods, making discount retailers like Walmart increasingly crucial for household budgets.

Despite the headwinds in its pharmacy segment, Walmart raised its full-year sales and earnings outlook, buoyed by robust growth in its online business, which saw a 24% increase in U.S. e-commerce sales. Analysts will be closely monitoring how the company leverages its omnichannel strategy and implements cost efficiencies to sustain growth amidst evolving market dynamics and consumer behaviors.